SEOUL - After completing Phase I clinical trials with its biosimilar versions of Herceptin (trastuzumab) and Aranesp (darbepoetin alfa) in Japan and Europe respectively, Dong-A Socio Holdings is now seeking global partnerships for the two products, possibly reaching deals this year or early next year to proceed with late stage global clinical trials, which will require a hefty amount of funding.
The group is aiming to launch its first biosimilar product, the Herceptin biosimilar, in Japan in 2019, but in the...